FOXO subsidiary Vector BioSource to acquire four blood collection centers from Grifols

FOXO TECHNOLOGIES INC.

Acquisition structured as asset purchase with upfront cash and potential earnout based on EBITDA targets in 2026-2028.
Expected to add over $10M in net revenues in 12 months post-closing from sale of whole blood, serum, and other bio-samples.
Closing anticipated in Q3 or Q4 2026, subject to FDA licensure and other regulatory authorizations.
Acquisition intended to provide proprietary bio-products and expand Vector's accessible market via new FDA licensure.
Vector CEO cites milestone in evolving from biospecimen sourcing to integrated biospecimen solutions company.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.